The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2018 | DUO results: duvelisib or ofatumumab monotherapy for R/R CLL?
Stephan Stilgenbauer
• 25 Oct 2018
The Phase III DUO trial investigated duvelisib vs. ofatumumab for chronic lymphocytic leukemia (CLL) in the relapsed/refractory setting (NCT02004522). Here, Stephan Stilgenbauer, MD, of the University of Ulm, Ulm, Germany, tells us about the final results of the trial, speaking from the European Research Initiative on CLL (ERIC) International Meeting 2018, held in Barcelona, Spain.
